

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

Human/Mouse/Rat Phospho-FRS2 (Y436) Antibody

RRID:AB_2106234

Type: Antibody

Proper Citation

R and D Systems Cat# AF5126, RRID:AB_2106234

Antibody Information

URL: http://antibodyregistry.org/AB_2106234

Proper Citation: R and D Systems Cat# AF5126, RRID:AB_2106234

Target Antigen: FRS2

Host Organism: Rabbit

Clonality: polyclonal

Comments: Applications: Western Blot, Immunocytochemistry

Antibody Name: Human/Mouse/Rat Phospho-FRS2 (Y436) Antibody

Description: This polyclonal targets FRS2

Target Organism: rat, mouse, human

Antibody ID: AB_2106234

Vendor: R and D Systems

Catalog Number: AF5126

Alternative Catalog Numbers: AF5126-SP

Record Creation Time: 20250820T043742+0000

Record Last Update: 20250820T192940+0000

Ratings and Alerts

No rating or validation information has been found for Human/Mouse/Rat Phospho-FRS2 (Y436) Antibody.

No alerts have been found for Human/Mouse/Rat Phospho-FRS2 (Y436) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Park JS, et al. (2022) Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein. Cell reports, 41(4), 111545.

Narla ST, et al. (2021) Loss of Fibroblast Growth Factor Receptor 2 (FGFR2) Leads to Defective Bladder Urothelial Regeneration after Cyclophosphamide Injury. The American journal of pathology, 191(4), 631.

Williams CM, et al. (2021) Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(2), e21286.

Narla ST, et al. (2020) Keratinocyte Growth Factor Reduces Injury and Leads to Early Recovery from Cyclophosphamide Bladder Injury. The American journal of pathology, 190(1), 108.

Liu PCC, et al. (2020) INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PloS one, 15(4), e0231877.

Neff AM, et al. (2019) Chronic Exposure of Mice to Bisphenol-A Alters Uterine Fibroblast Growth Factor Signaling and Leads to Aberrant Epithelial Proliferation. Endocrinology, 160(5), 1234.